fda compounding semaglutide warning november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots FDA issued 25 warning letters

Mounjaro (tirzepatide) is a similar option for Type 2 diabetes that is classified as a dual GIP/GLP-1 receptor agonist

Additionally, semaglutide should not be used concurrently with other GLP-1 receptor agonists

Patients taking a GLP-1 need to be supported by multidisciplinary care teams that practice strong patient education strategies

In clinical trials, there were no severe adverse events

Antioxidants are extremely beneficial in promoting overall health on the cellular level because they help protect cells against damage they sustain with everyday exposure to free radicals in the environment

Dry mouth is not just uncomfortable